<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907114</url>
  </required_header>
  <id_info>
    <org_study_id>HJM 1667/09.03.24</org_study_id>
    <nct_id>NCT00907114</nct_id>
  </id_info>
  <brief_title>Topic Ketorolac Added to Panphotocoagulation in Proliferative Diabetic Retinopathy</brief_title>
  <official_title>Efficacy and Safety of Topic Ketorolac to Treat Center Point Thickness Secondary to Panphotocoagulation in Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Juarez de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Juarez de Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of topic ketorolac in
      treatment for center point thickness secondary to panphotocoagulation in proliferative
      diabetic retinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Panphotocoagulation is the standard treatment for proliferative diabetic retinopathy during 3
      to 4 sessions within 2 weeks. This treatment reduces the incidence of severe visual loss in
      the long term. Nonetheless, it induces macular thickness that delays the conclusion of the
      treatment. This delay could coincide with vitreous hemorrhage which, in turn, may limit
      additional photocoagulation.

      Topic ketorolac could limit the inflammatory reaction cause by panphotocoagulation and
      produce early benefits in the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>center subfield mean thickness using Stratus OCT measured in microns</measure>
    <time_frame>baseline, 24, 48 and 168 hours after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>center point thickness using Stratus OCT, measured in microns</measure>
    <time_frame>baseline, 24, 48 and 168 hours after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>macular volume using Stratus OCT, measured in cubic millimeters</measure>
    <time_frame>baseline, 24, 48 and 168 hours after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ocular topic ketorolac used 4 times a day during a week after panphotocoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polivynilic alcohol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ocular lubricant drops 4 times a day during one week after panphotocoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac tromethamine</intervention_name>
    <description>Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation</description>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
    <other_name>Godek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polivynilic alcohol</intervention_name>
    <description>Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation</description>
    <arm_group_label>Polivynilic alcohol</arm_group_label>
    <other_name>Acuafil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  proliferative diabetic retinopathy

          -  without macular edema

          -  adequate quality 6 mm fast macular map on the day of treatment

          -  visual capacity under subjective refraction before treatment

          -  signed of inform consent

        Exclusion Criteria:

          -  ocular surgery in the last 4 months

          -  myopia over -6.00 diopters

          -  allergy to ketorolac or non-steroids antiinflammatory

          -  previous selective photocoagulation

          -  using non-steroids antiinflammatory or immunomodulators

          -  intraocular inflammatory

          -  any retinal disease different from diabetic retinopathy

          -  pregnancy

          -  actual corneal disease

          -  inadequate quality 6 mm fast macular map after the second visit

          -  inconsistency after the second visit

          -  adverse event of the drug

          -  remove of the inform consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virgilio Lima Gomez, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Juarez de Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dulce M Razo Blanco Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Juarez de Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Asbun Bojalil, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Juarez de Mexico</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virgilio Lima Gomez</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>07760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Juarez de Mexico</investigator_affiliation>
    <investigator_full_name>Virgilio Lima Gomez</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>proliferative diabetic retinopathy</keyword>
  <keyword>macular edema</keyword>
  <keyword>panphotocoagulation</keyword>
  <keyword>topic ketorolac</keyword>
  <keyword>efficacy</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

